Zalicus Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 83

Zalicus Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Zalicus Inc. - Product Pipeline Review - 2012” provides data on the Zalicus Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Zalicus Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Zalicus Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Zalicus Inc. - Brief Zalicus Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Zalicus Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Zalicus Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Zalicus Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Zalicus Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Zalicus Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Zalicus Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Zalicus Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Zalicus Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Zalicus Inc.; Zalicus Inc. - Key Therapeutics; Zalicus Inc. - Pipeline Overview and Promising Molecules; Zalicus Inc. - News; Zalicus Inc. - Latest Updates; Zalicus Inc. - Pipeline; Zalicus Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Zalicus Inc. Snapshot
Zalicus Inc. Overview
Key Information
Key Facts
Zalicus Inc. – Research and Development Overview
Key Therapeutic Areas
Zalicus Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Zalicus Inc. – Pipeline Products Glance
Zalicus Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Zalicus Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Zalicus Inc. – Drug Profiles
CRx-102
Product Description
Mechanism of Action
R&D Progress
Oncology Program
Product Description
Mechanism of Action
R&D Progress
Synavive
Product Description
Mechanism of Action
R&D Progress
Z160
Product Description
Mechanism of Action
R&D Progress
Z944
Product Description
Mechanism of Action
R&D Progress
Zalicus Inc. – Pipeline Analysis
Zalicus Inc. – Pipeline Products by Therapeutic Class
Zalicus Inc. – Pipeline Products By Target
Zalicus Inc. – Pipeline Products by Route of Administration
Zalicus Inc. – Pipeline Products By Mechanism of Action
Zalicus Inc. – Recent Pipeline Updates
Zalicus Inc. - Dormant Projects
Zalicus Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CRx-140
CRx-139
CRx-150
CRx-401
Zalicus Inc. – Company Statement
Zalicus Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Zalicus Inc., Recent Developments
Zalicus Inc.- Press Release
May 02, 2012: Zalicus Advances Z160 Into Multiple Phase IIa Clinical Trials For Treatment Of Pain
Apr 30, 2012: Zalicus Completes Patient Enrollment In Phase IIb Clinical Trial Of Synavive In Rheumatoid Arthritis
Mar 05, 2012: Zalicus Completes Phase I Clinical Study With Reformulated Z160
Feb 15, 2012: University Of British Columbia Researchers Develop New Drugs To Treat Absence Seizures
Feb 15, 2012: Zalicus Publishes Preclinical Data Of New Ion Channel Compound, Z944 In Science Translational Medicine
Oct 21, 2009: CombinatoRx's Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
Oct 21, 2009: CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
Jun 11, 2009: Neuromed Pharmaceuticals Announces that Merck Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
May 27, 2009: CombinatoRx Reports Positive Phase II Trial Results For CRx-401
Financial Deals Landscape
Zalicus Inc., Deals Summary
Zalicus Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
CombinatoRx Secures $30 Million In Third Round Of Financing
Partnerships
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain
CombinatoRx Enters Into Research Collaboration With Charley's Fund And THE NASH AVERY
Gene Network Sciences Enters Into Research Collaboration Agreement With CombinatoRx
CombinatoRx Signs An Agreement With Cystic Fibrosis Foundation Therapeutics
CombinatoRx Signs Agreement With Fovea Pharma
CombinatoRx Enters Into Research Agreement With CHDI
CombinatoRx Enters Into Co-Development Agreement With ABC2
CombinatoRx Enters Into Research And Development Collaboration Agreement With Spinal Muscular Atrophy Foundation
Merger
CombinatoRx Completes Merger With Neuromed
Licensing Agreements
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research
Clinical Data Enters Into License Agreement With CombinatoRx
CombinatoRx Enters Into Licensing Agreement With Novartis Institutes For BioMedical Research
Angiotech Pharma Extends Licensing Agreement With CombinatoRx
CombinatoRx Enters Into Licensing Agreement With Fovea Pharma
CombinatoRx Enters Into Research And Licensing Agreement With Angiotech Pharma
CombinatoRx Enters Into Licensing Agreement With HenKan Pharma
Equity Offering
Zalicus Files Shelf Registration Statement For Public Offering Of $15 Million
Zalicus Completes Second Tranche Of Private Placement Of Shares For $4.25 Million
CombinatoRx Completes Private Placement Of $35 Million
CombinatoRx Completes Private Placement Of $48 Million
CombinatoRx Completes IPO Of $48 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Zalicus Inc., Key Information
Zalicus Inc., Key Facts
Zalicus Inc. – Pipeline by Indication, 2012
Zalicus Inc. – Pipeline by Stage of Development, 2012
Zalicus Inc. – Monotherapy Products in Pipeline, 2012
Zalicus Inc. – Phase II, 2012
Zalicus Inc. – Phase I, 2012
Zalicus Inc. – Pre-Clinical, 2012
Zalicus Inc. – Discovery, 2012
Zalicus Inc. – Pipeline By Therapeutic Class, 2012
Zalicus Inc. - Pipeline By Target, 2012
Zalicus Inc. – Pipeline By Route of Administration, 2012
Zalicus Inc. – Pipeline Products By Mechanism of Action, 2012
Zalicus Inc. – Recent Pipeline Updates, 2012
Zalicus Inc. - Dormant Developmental Projects,2012
Zalicus Inc. - Discontinued Pipeline Products, 2012
Zalicus Inc., Subsidiaries
Zalicus Inc., Deals Summary
CombinatoRx Secures $30 Million In Third Round Of Financing
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain
CombinatoRx Enters Into Research Collaboration With Charley's Fund And THE NASH AVERY
Gene Network Sciences Enters Into Research Collaboration Agreement With CombinatoRx
CombinatoRx Signs An Agreement With Cystic Fibrosis Foundation Therapeutics
CombinatoRx Signs Agreement With Fovea Pharma
CombinatoRx Enters Into Research Agreement With CHDI
CombinatoRx Enters Into Co-Development Agreement With ABC2
CombinatoRx Enters Into Research And Development Collaboration Agreement With Spinal Muscular Atrophy Foundation
CombinatoRx Completes Merger With Neuromed
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research
Clinical Data Enters Into License Agreement With CombinatoRx
CombinatoRx Enters Into Licensing Agreement With Novartis Institutes For BioMedical Research
Angiotech Pharma Extends Licensing Agreement With CombinatoRx
CombinatoRx Enters Into Licensing Agreement With Fovea Pharma
CombinatoRx Enters Into Research And Licensing Agreement With Angiotech Pharma
CombinatoRx Enters Into Licensing Agreement With HenKan Pharma
Zalicus Files Shelf Registration Statement For Public Offering Of $15 Million
Zalicus Completes Second Tranche Of Private Placement Of Shares For $4.25 Million
CombinatoRx Completes Private Placement Of $35 Million
CombinatoRx Completes Private Placement Of $48 Million
CombinatoRx Completes IPO Of $48 Million

List of Figures
Zalicus Inc. – Pipeline by Indication, 2012
Zalicus Inc. – Pipeline by Stage of Development, 2012
Zalicus Inc. – Monotherapy Products in Pipeline, 2012
Zalicus Inc. – Pipeline By Therapeutic Class, 2012
Zalicus Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Ixia - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Dell Inc.
• eBay - Strong Execution
• SunGard - Profile - US
• Tektronix, Inc.